Lung Function
FDA approves Ohtuvayre as maintenance treatment for COPD
The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.
Buloxibutid well tolerated, increases lung function in IPF
SAN DIEGO — Among patients with idiopathic pulmonary fibrosis, twice-daily buloxibutid for 36 weeks significantly improved FVC, according to research presented at the American Thoracic Society International Conference.
Young smoker CT scans show lung abnormalities, lung function loss over 3 years
SAN DIEGO — Lung abnormalities appeared more frequently on CT scans from young current smokers vs. never smokers, according to research presented at the American Thoracic Society International Conference.
Adults with food insecurity have reduced lung function, elevated COPD symptom burden
SAN DIEGO — Lung function decreased and COPD symptom burden increased among adults with vs. without food insecurity, according to research presented at the American Thoracic Society International Conference.
Hedgehog pathway inhibitor safe, improves lung function in IPF
SAN DIEGO — After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to research presented at the American Thoracic Society International Conference.
Dupilumab lowers exacerbations, betters lung function in COPD with type 2 inflammation
SAN DIEGO — With dupilumab vs. placebo, adults with moderate to severe COPD and type 2 inflammation experienced fewer exacerbations, according to research presented at the American Thoracic Society International Conference.
Race-neutral lung function equations alter disease classification, disability compensation
SAN DIEGO — Millions of individuals had different clinical, occupational and financial outcomes with race-neutral vs. -specific lung function equations, according to a presentation at the American Thoracic Society International Conference.
Dupilumab associated with significant reductions in mucus plugging, volume
SAN DIEGO — Patients with asthma experienced significant reductions in mucus airway plugging and mucus volume with dupilumab, according to a presentation at the American Thoracic Society International Conference.
Biologics lower exacerbations, hospitalizations in COPD, Th2 inflammation
SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.
Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD
SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.